We reported a case of a 70-year-old man with kidney malignancy who developed SJS after receiving the combination therapy of axitinib (anti-VEGFR TKI) and tislelizumab (anti-PD-1 monoclonal antibody). This evidence concerns the gene KDR and Schwartz-Jampel syndrome.